- The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated the first Phase 3 clinical trial for India’s indigenous tetravalent dengue vaccine, DengiAll.
- It builds on strains (TV003/TV005) created by the U.S. National Institutes of Health.
- Panacea Biotec, one of three Indian companies to receive the vaccine strain holds a process patent.
- The trial is primarily funded by ICMR and involves a two-year follow-up with participants.
Dig Deeper: Read about the development of indigenous vaccines for Tuberculosis and cholera.
